Actively Recruiting
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
Led by The First Affiliated Hospital of Soochow University · Updated on 2023-04-07
60
Participants Needed
1
Research Sites
261 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate the efficacy and safety of venetoclax combined with homoharringtonine and cytarabine in the treatment of newly diagnosed acute myeloid leukemia.
CONDITIONS
Official Title
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must be between 18 and 60 years old
- Diagnosed with acute myeloid leukemia (AML) according to WHO criteria and never treated before
- Eligible for intensive chemotherapy based on heart, lung, kidney, and liver function criteria
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 or less
- Laboratory values within specified limits including creatinine clearance ≥ 45 mL/min, AST and ALT ≤ 3 times upper limit of normal, total bilirubin ≤ 1.5 times upper limit of normal, and white blood cell count less than 25 × 10^9/L (hydroxyurea allowed)
You will not qualify if you...
- Younger than 18 or older than 60 years
- Diagnosis of acute promyelocytic leukemia (M3)
- Ineligible for treatment with intensive chemotherapy
- Active uncontrolled infection or active bleeding from vital organs
- History of significant drug or alcohol abuse affecting study participation
- Significant medical or psychiatric conditions that would interfere with the study
- Female who are pregnant, breastfeeding, or of childbearing potential without negative pregnancy test
- Uncontrolled infection with HIV or active hepatitis B or C
- Deemed unsuitable for enrollment by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Qiu Huiying
Suzhou, Jiangsu, China, 215006
Actively Recruiting
Research Team
H
Huiying Qiu, PhD
CONTACT
D
Depei Wu, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here